Results 121 to 130 of about 2,710 (165)
Some of the next articles are maybe not open access.
Drugs of Today, 2007
Aliskiren (CGP-60536 or SPP100) is the first oral direct renin inhibitor and the first new class of antihypertensive agents to be introduced in more than a decade. Aliskiren taken once a day, alone or in combination with other antihypertensive agents, has been shown to be effective in reducing blood pressure and is generally well tolerated. Based on an
Helmy M. Siragy +2 more
+13 more sources
Aliskiren (CGP-60536 or SPP100) is the first oral direct renin inhibitor and the first new class of antihypertensive agents to be introduced in more than a decade. Aliskiren taken once a day, alone or in combination with other antihypertensive agents, has been shown to be effective in reducing blood pressure and is generally well tolerated. Based on an
Helmy M. Siragy +2 more
+13 more sources
RENIN INHIBITION WITH ALISKIREN
Clinical and Experimental Pharmacology and Physiology, 2008SUMMARY Initial attempts to inhibit renin in humans have faced numerous difficulties. Molecular modelling and X‐ray crystallography of the active site of renin have led to the development of new orally active renin inhibitors, such as aliskiren. Aliskiren has a low bioavailality (between 2.6 and 5.0%) compensated by its high potency to inhibit renin ...
Grégoire, Wuerzner, Michel, Azizi
openaire +2 more sources
Aliskiren in the Management of Hypertension
American Journal Cardiovascular Drugs, 2010Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers) have been shown to be effective drugs in the management of hypertension and to have beneficial effects along the cardiovascular continuum.
Vivencio, Barrios, Carlos, Escobar
openaire +2 more sources
Formal Total Synthesis of Aliskiren
Chemistry – A European Journal, 2015AbstractThe efficient and selective formal total synthesis of aliskiren is described. Aliskiren, a renin inhibitor drug, has received considerable attention, primarily because it is the first of the renin inhibitor drugs to be approved by the FDA. Herein, the formal synthesis of aliskiren by iridium‐catalyzed asymmetric hydrogenation of two allylic ...
Peters, B. K. +3 more
openaire +3 more sources
▼Aliskiren for hypertension in adults
Drug and Therapeutics Bulletin, 2008High blood pressure is a major risk factor for cardiovascular disease worldwide.1 Drug treatments include those that target the renin-angiotensin system, a key hormone cascade in the regulation of blood pressure. One of these is ▼aliskiren (Rasilez – Novartis), which belongs to a new class of drugs, direct renin inhibitors.2 Here we assess its place in
openaire +2 more sources
Is There a Place on the Shelf for Aliskiren?
Current Cardiovascular Risk Reports, 2010Increased renin-angiotensin-aldosterone system (RAAS) activity contributes to target-organ damage and increases cardiovascular risk by elevating blood pressure (BP) and through direct effects on the heart, kidneys, brain, and vascular endothelium. Pharmacologic blockade of RAAS effectively reduces BP and limits or reverses various forms of target-organ
openaire +3 more sources